Logo Logo
Hilfe
Hilfe
Switch Language to English

Haidari, Selgai; Tröltzsch, Matthias; Fliefel, Riham; Jungbluth, Achim A.; Otto, Sven; Fegg, Florian; Liokatis, Paris; Ahmadi, Nima; Eberl, Marian; Probst, Florian Andreas und Knösel, Thomas (2022): Cancer testis antigen (PRAME) as an independent marker for survival in oral squamous cell carcinoma (OSCC). In: Journal of Oral Pathology & Medicine, Bd. 51, Nr. 5: S. 421-428 [PDF, 1MB]

Abstract

Background The objective was to assess the expression patterns of the cancer testis antigen PRAME, NY-ESO1, and SSX2 in oral squamous cell carcinoma (OSSC) and to correlate the expression with clinical and histopathological parameters including progression-free survival analysis. Methods The study variables of this retrospective cohort study (n = 83) included demographic data, histopathological data, and information on progression-free survival. PRAME expression patterns were rated based on immunohistochemistry on tissue microarrays (TMA). The survival rate was assessed by Kaplan-Meier method and Cox regression model. The primary predictor variable was defined as the expression of PRAME and the outcome variable was progression-free survival. Results Analysis of progression-free survival using Kaplan-Meier method showed that patients with positive expression of PRAME had lower probabilities of progression-free survival (p < 0.001). According to the Cox regression model, the level of PRAME expression had a considerable and significant independent influence on progression-free survival (positive PRAME expression increasing the hazards for a negative outcome by 285% in our sample;HR = 3.85, 95% CI: 1.45-10.2, p = 0.007). The expression of SSX2 (n = 1) and NY-ESO-1 (n = 5) in our samples was rare. Conclusion PRAME is expressed in OSCC and appears to be a suitable marker of progression-free survival, correlates with severe course, and may allow identification of high-risk patients with aggressive progression.

Dokument bearbeiten Dokument bearbeiten